Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

JP Morgan Maintains Underweight on BioNTech, Lowers Price Target to $91

Author: Benzinga Newsdesk | August 15, 2024 08:07am
JP Morgan analyst Jessica Fye maintains BioNTech (NASDAQ:BNTX) with a Underweight and lowers the price target from $94 to $91.

Posted In: BNTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist